Cargando…

Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

BACKGROUND: Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been deciphered and possible drug target trials a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Halder, Umesh C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331326/ https://www.ncbi.nlm.nih.gov/pubmed/34344455 http://dx.doi.org/10.1186/s40709-021-00149-2

Ejemplares similares

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir
por: Yu, Yuqi, et al.
Publicado: (2015)

Optical Resolution of Rimantadine
por: Han, Jianlin, et al.
Publicado: (2019)

Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations
por: Chen, Jianzhong, et al.
Publicado: (2014)

Lack of antiviral activity of darunavir against SARS-CoV-2
por: De Meyer, Sandra, et al.
Publicado: (2020)

A combined study on structures and vibrational spectra of the antiviral rimantadine using SQMFF and DFT calculations
por: Iramain, Maximiliano A., et al.
Publicado: (2022)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

Synthesis of Three Rimantadine Schiff Bases and Their Biological Effects on Serum Albumin
por: Liu, Bing-Mi, et al.
Publicado: (2014)

Elimination of Solanum nigrum ilarvirus 1 and Apple Hammerhead Viroid from Apple Cultivars Using Antivirals Ribavirin, Rimantadine, and Zidovudine
por: Sedlák, Jiří, et al.
Publicado: (2023)

In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
por: Buitrón-González, Ivonne, et al.
Publicado: (2021)

Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells
por: Pereira, Mariana, et al.
Publicado: (2022)

Molecular docking and simulation studies of Chloroquine, Rimantadine and CAP-1 as potential repurposed antivirals for decapod iridescent virus 1 (DIV1)
por: Azemin, Wan-Atirah, et al.
Publicado: (2023)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro
por: Samuels, Tina L., et al.
Publicado: (2023)

Combined anti-influenza virus effect of a plant polyphenol-rich extract and rimantadine
por: Serkedjieva, J., et al.
Publicado: (2006)

Metabolic profiling to evaluate the impact of amantadine and rimantadine on the secondary metabolism of a model organism
por: Kostina-Bednarz, Marianna, et al.
Publicado: (2023)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages
por: Borrajo, Ana, et al.
Publicado: (2017)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA
por: Bello, Martiniano, et al.
Publicado: (2020)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
por: Bawdon, R E
Publicado: (1998)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Darunavir does not prevent SARS-CoV-2 infection in HIV patients
por: Riva, Agostino, et al.
Publicado: (2020)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
por: Blaine-Sauer, Simon, et al.
Publicado: (2023)

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
por: Fang, Yan, et al.
Publicado: (2022)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
por: Huang, Kuan-Ying A., et al.
Publicado: (2023)

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
por: Scott, Claire, et al.
Publicado: (2020)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fhqbpnofqrnrpv98g8ilfu7ubq